ARTICLE | Clinical News

NObreath regulatory update

April 14, 2014 7:00 AM UTC

The U.K.'s NICE issued final guidance recommending Niox Mino and Niox Vero from Aerocrine AB (SSE:AERO, Solna, Sweden) and NObreath from Bedfont to help diagnose and manage eosinophilic asthma. The tests are recommended for use in subjects who, after initial clinical examination, are considered to have an intermediate probability of having asthma and when fractional exhaled nitric oxide (FeNO) testing is done in combination with other diagnostic options. Additionally, FeNO measurement is recommended to support the management of symptomatic asthma in subjects who still have symptoms despite being treated with inhaled corticosteroids. The guidance is in line with preliminary guidelines issued last year (see BioCentury, Nov. 18, 2013). ...